RHETORIC FIRST, ACTION LATER: THE G7 APPROACH TO GLOBAL EQUITY

RHETORIC FIRST, ACTION LATER: THE G7 APPROACH TO GLOBAL EQUITY

News
WEEKLY COVID VACCINE RESEARCH UPDATE MONDAY, FEBRUARY 22, 2021 Data Updates High-income country confirmed dose total: 4.6 billion Upper-middle-income country total: 1.3 billion Lower-middle-income country total: 631 million Low-income country total: 671 million COVAX total: 1.12 billion Total worldwide confirmed purchases of Covid-19 vaccines: 8.25 billion doses Weekly Insights and Interesting Trends Author: Andrea Taylor Rhetoric first, action later: the G7 approach to global equity The G7 countries met (virtually) on Friday, February 19, to share variants of “no one is safe until everyone is safe” and discuss the importance of global equity of Covid-19 vaccines and the need for international cooperation. (Sound familiar? That’s because we heard the same things from the G20 in November.) The countries together pledged another $7.5 billion in funding for COVAX (including the $4 billion that the US Congress set aside for…
Read More
VACCINE HESITANCY WILL SOON BECOME THE PRIMARY OBSTACLE TO GLOBAL IMMUNITY

VACCINE HESITANCY WILL SOON BECOME THE PRIMARY OBSTACLE TO GLOBAL IMMUNITY

News
WEEKLY COVID VACCINE RESEARCH UPDATE TUESDAY, FEBRUARY 16, 2021 Data Updates High-income country confirmed dose total: 4.6 billion Upper-middle-income country total: 1.2 billion Lower-middle-income country total: 599 million Low-income country total: 670 million COVAX total: 1.12 billion Total worldwide confirmed purchases of Covid-19 vaccines: 8.2 billion doses Weekly Insights and Interesting Trends Author: Andrea Taylor Vaccine hesitancy will soon become the primary obstacle to global immunity Global manufacturing capacity has been the primary rate limiter for Covid-19 vaccinations. Our vaccine manufacturing infrastructure was not designed to produce enough doses to cover 70% of the world’s population within a year (in addition to regular and routine vaccines) and, as expected, demand is outstripping supply. There has been good news on the manufacturing front, however, with several large pharma companies recently joining with…
Read More
COVAX RELEASED DRAFT ALLOCATIONS FOR THE FIRST HALF OF 2021

COVAX RELEASED DRAFT ALLOCATIONS FOR THE FIRST HALF OF 2021

News
WEEKLY COVID VACCINE RESEARCH UPDATE MONDAY, FEBRUARY 8, 2021 Data Updates High-income country confirmed dose total: 4.2 billion Upper-middle-income country total: 1.2 billion Lower-middle-income country total: 582 million Low-income country total: 670 million COVAX total: 1.11 billion Total worldwide confirmed purchases of Covid-19 vaccines: 7.8 billion doses Weekly Insights and Interesting Trends Author: Andrea Taylor COVAX released draft allocations for the first half of 2021 The COVAX partnership released last week its first estimates of dose allocations for participating countries, covering planned deliveries from February through June. These are labeled as “indicative,” meaning the estimates are non-binding and subject to a list of caveats provided in both the distribution forecast and the supply update released in January. In fact, the language surrounding both documents seems on balance to contain more hedging than forecasting. This is…
Read More
WHAT IS AT STAKE IN EU’S MOVE TO CONTROL VACCINE EXPORTS

WHAT IS AT STAKE IN EU’S MOVE TO CONTROL VACCINE EXPORTS

News
WEEKLY COVID VACCINE RESEARCH UPDATE MONDAY, FEBRUARY 1, 2021 [caption id="attachment_1474" align="alignnone" width="329"] Source: © WHO / Gregor Donaldson[/caption] Data Updates High-income country confirmed dose total: 4.2 billion Upper-middle-income country total: 1.2 billion Lower-middle-income country total: 524 million Low-income country total: 670 million COVAX total: 1.11 billion Total worldwide confirmed purchases of Covid-19 vaccines: 7.2 billion doses Weekly Insights and Interesting Trends Author: Andrea Taylor What is at Stake in EU’s Move to Control Vaccine Exports AstraZeneca recently alerted the EU that it would only be able to deliver 25% of the 80-100 million doses of Covid-19 vaccine expected this quarter, due to production problems in the European plants. The EU responded by suggesting, in the firmest of tones, that AstraZeneca divert doses from the (recently Brexited) UK manufacturing plants…
Read More